NOXXON Pharma gibt erste Tranche von Odirnane-Wandelschuld-verschreibungen ausWeiterlesen...
NOXXON gibt Prospektveröffentlichung und Transfer der Aktien in das öffentliche Handelssegment des Euronext Growth bekanntWeiterlesen...
NOXXON gibt Behandlung der ersten Patienten einer klinischen Phase 1/2-Studie mit NOX-A12 in Kombination mit KEYTRUDA® bei metastasierendem Bauchspeicheldrüsen- und Darmkrebs bekanntWeiterlesen...
NOXXON Pharma kündigt Zusammenarbeit mit Nationalem Zentrum für Tumorerkrankungen in Heidelberg bei NOX-A12/Keytruda® Phase 1/2 Kombinationsstudie anWeiterlesen...
NOXXON PHARMA secures a private placement of €1 million and additional financing of up to €10 million through convertible notes with share subscritpion warrants attached to finance further clinical development of NOX-A12Weiterlesen...
Focus on Oncology Clinical Development allows Recruitment of Specialist involved in Approval of multiple Oncology Agents
Berlin, Germany, February 10, 2017 - NOXXON Pharma N.V. (Alternext Paris: ALNOX), a biotechnology company whose core focus is on cancer treatment, has today announced that Jarl Ulf Jungnelius, M.D., Ph.D. will take over the role of Chief Medical Officer. Dr. Jungnelius, who is already familiar with the company’s programs in a consulting capacity, will now increase his involvement with NOXXON, allowing for a period of overlap with Dr. Matthias Baumann whose current contract as Chief Medical Officer expires in June 2017.
Dr. Jungnelius’ career includes leadership positions at Celgene, Pfizer, Takeda and Eli Lilly & Company and significant roles in the approval of several successful oncology drugs including Abraxane®, Gemzar®, Alimta® and Revlimid®. Of particular relevance to NOXXON is his prior experience in immune-oncology and his involvement with two agents that have been approved for pancreatic cancer, one of the indications pursued in the upcoming clinical trial of NOX-A12 in combination with Keytruda® which will be conducted in collaboration with Merck & Co. / MSD.
“I am pleased to take on the role of CMO to work with the NOXXON team and excited by the opportunity to work with agents targeting the tumor microenvironment which I believe is an approach with significant potential for patients,” commented Dr. Jarl Ulf Jungnelius.
“Jarl Ulf is a great fit for NOXXON as we continue our transition to a clinical oncology company. His extensive experience in oncology clinical development in the US and Europe will be invaluable as we develop NOX-A12 to target the tumor microenvironment,” commented Dr. Aram Mangasarian, CEO of NOXXON.
“On behalf of the board I want to thank Matthias for all excellent work he has done for NOXXON Pharma across multiple programs in the last years and for the professional and pragmatic way he is managing this transition,” commented Dr. Hubert Birner, Chairman of NOXXON.
Further Information about Dr. Jarl Ulf Jungnelius
Jarl Ulf Jungnelius, M.D., Ph.D. worked at Celgene from 2007 to 2014 where he served as Vice President of Clinical Research and Development, Solid Tumors. Prior to that post Dr. Jungnelius held leadership positions at Takeda, Pfizer and Eli Lilly & Company, where he was responsible for clinical development of oncology programs as well as involved in business development. Dr. Jungnelius held important responsibilities in the clinical development of several successful oncology drugs, including Abraxane®, Gemzar®, Alimta® and Revlimid®. He is an oncologist with more than 25 years of clinical and research experience at both large pharmaceutical companies and academic organizations. Dr. Jungnelius is currently Chief Medical Officer at VAXIMM, Supervisory Board director of Isofol Medical AB, Biovica International AB and Monocl AB and has been a director at Oncopeptides AB since April 2011. He received both a Bachelor of Science degree and his M.D. from the Karolinska Institute in Stockholm Sweden.